Videos

Kami Maddocks, MD, reviews the case of a 74-year-old man with relapsed/refractory follicular lymphoma and discusses current treatment options.

Anthony Mato, MD, MSCE, discusses the use of a triplet combination of the novel Bruton tyrosine kinase inhibitor DTRMWXHS-12, the mTOR inhibitor, everolimus, and the IMiD pomalidomide for the treatment of relapsed/refractory Richter’s transformation and de novo diffuse large B-cell lymphoma.

William H. Bradley, MD discusses the 5-year follow-up of the ongoing SOLO-1 trial, which is determining the efficacy of maintenance olaparib in patients with BRCA1/2-mutated advanced ovarian cancer.

Oliver Sartor, MD, reviews clinical data from the TheraP trial looking at the activity of 177Lu-PSMA617 in patients with metastatic castration-resistant prostate cancer.

Key opinion leaders expand on the broad clinical utility of prostate-specific membrane antigen (PSMA) for patients with advanced prostate cancer.

Hutson and Choueiri compare the safety profiles of lenvatinib + pembrolizumab against other TKI/IO combinations for patients with metastatic clear-cell renal cell carcinoma.

Frederick Locke, MD, addresses the ongoing unmet needs for patients with mantle cell lymphoma such as the role of novel agents in the upfront setting.

Frederick Locke, MD, considers whether CAR T will gain a more significant role in mantle cell lymphoma and if it will move to the frontline setting.

Thomas Hutson, DO, PharmD, and Toni Choueiri, MD, talk about the phase 3 CLEAR trial at length, including each of the 3 arms of the trial and key data.

Rafael Fonseca, MD, reviews efficacy and safety data from the phase 3 MAIA trial and discusses their implications for clinical practice.

Hutson and Choueiri elaborate on the FDA-approved TKI + ICI combinations and their data from the following trials: KEYNOTE-146, JAVELIN Renal 101, and CheckMate-9ER.

Rafael Fonseca, MD, discusses the role of monoclonal antibodies in the first-line setting in patients with newly diagnosed multiple myeloma.

Frederick Locke, MD, explains when to choose CAR T over BTK inhibitors, patient factors to consider for CAR T cell therapy, and when BTK inhibitors are best utilized.

Toni Choueiri, MD, focuses on combining VEGF-tyrosine kinase inhibitors with immune checkpoint inhibitors in metastatic clear-cell renal cell carcinoma.

Frederick Locke, MD, discusses the role of CAR T in patients with mantle cell lymphoma, the impact it has on autologous transplant, and when transplant is recommended.

Rafael Fonseca, MD, reviews first-line therapy options and considerations for treatment selection for patients with newly diagnosed multiple myeloma.

Thomas Hutson, DO, PharmD, and Toni Choueiri, MD, discuss the available biomarkers, predictive biomarkers, and clinical predictors that are currently used in metastatic clear-cell renal cell carcinoma, as well as risk status.

Frederick Locke, MD, discusses the ZUMA-2 trial, including the study design, results, and practical implications for CAR T in patients with mantle cell lymphoma.

Rafael Fonseca, MD, discusses the challenges of treating patients with newly diagnosed multiple myeloma.

Rafael Fonseca, MD, reviews the case overview of a 77-year-old woman with multiple myeloma.

Frederick Locke, MD, reviews the treatment options historically available to patients with mantle cell lymphoma who had disease recurrence after high-dose therapy and transplant.

Frederick Locke, MD, discusses treatment options for patients with mantle cell lymphoma and the use of CAR T-cell therapy in clinics.

Rafael Fonseca, MD, discusses the case of a 77-year-old woman with multiple myeloma, treatment approach for patients with newly diagnosed multiple myeloma, and the trials providing insight into the treatment of this disease.

Srdan Verstovsek, MD, PhD, discusses the impacts of an analysis demonstrating longer survival in patients with myelofibrosis who received ruxolitinib versus those who didn’t.

An expert in the treatment of lung cancer gives insight for the sequencing of ALK inhibitors following disease progression, highlighting the instances of the development of brain involvement and rebiopsy.

Dr Lunning reviews potential options for later line therapy for patients with R/R DLBCL and shares his thought about future directions in the evolving treatment landscape.

An expert in the treatment of lung cancer gives insight for the sequencing of ALK inhibitors following disease progression, highlighting the instances of the development of brain involvement and rebiopsy.

Matthew Lunning, DO, presents the efficacy and safety findings of the L-MIND trial in relapsed/refractory diffuse large B-cell lymphoma and discusses the implications for clinical practice.

Karen Reckamp, MD, discusses the design, practical implications, and important findings from the ALTA-1L clinical trial.

An expert in the treatment of lung cancer discusses the use of brigatinib in this patient case and in general use for ALK+ metastatic NSCLC.